BioCapital Forum
Wednesday, October 14
- MassBioHub, 700 Technology Square 5th floor, Cambridge, MA
Overview
The BioCapital Forum is an invite-only, one-day gathering of family offices and
institutional LPs in Boston on Wednesday, October 14, 2026. It puts the senior
decision-makers shaping biotech capital in a single room for a grounded look at
the opportunity, and the relationships that make it investable. As capital crowds
into technology and AI, many life-science companies trade at valuations that
ignore the pace of the science, and the Forum makes the data-driven case for why
now.
Why attend
- Conviction to act: a working command of biotech fundamentals and the structural forces positioning the sector for long-term value creation.
- A direct line to the market: unfiltered insight from the investors, founders, and operators deploying capital in the sector today.
- A clear path in: how to source deal flow and co-invest alongside experiencedpartners.
- The right room: decision-makers only, no gatekeepers, no junior staff.
Who should attend
This room is built for principals, partners, and managing directors at family offices and institutional LPs, whether you are already investing in biotech or sizing it up as an asset class. Attendance is invite-only and deliberately capped to keep the room
senior: anyone may apply, and every applicant is vetted for credentials.
On the agenda
A single day built around education, marquee voices, and high-quality networking:
a market-setting keynote followed by panels on direct vs. fund investing, NewCo
formation, the AI-vs.-biotech debate, and how to begin investing in the space,
closing with a networking reception.
9:00–9:30 AM | Registration & Welcome Coffee Arrivals, badges, and informal networking over breakfast.
9:30–9:45 AM | Welcome & Opening Remarks Geoff Meyerson (Locust Walk & Banyan Bio) to deliver the opening remarks, framing the day’s purpose, the case for biotech as an asset class, and the U.S. private-venture market context.
A marquee investor or operator on the state of biotech investing and where the industry is heading. What are the opportunities to invest in US-based biotech companies
Trade-offs of going direct versus committing to funds; portfolio construction for LPs and family
offices. How to reconcile fees vs access and adverse selection
How new companies get built and financed, and where family offices and LPs can participate
Where AI is genuinely reshaping drug development versus where hype outpaces reality. How does investing into non-life science AI compete with life science investing. How do investors best use AI to source, diligence, and make investment decisions.
2:15–3:15 PM | Panel 4: How to Get Started If I Don’t Currently Make
Biopharma Investments For LPs that are not currently have an in-house diligence capability or believe that biopharma investing has not been an area of focus, this panel will discuss practical tools and suggestions on how to build this capability and diligence both funds and direct investments.
Synthesis of the day and next steps for the community.
Cocktails and curated introductions to close the day.
Partners
